Pretreatment 18F-FDG PET/CT in whole-body total lesion glycolysis to predict survival in patients with pharyngeal cancer treated with definitive radiotherapy

Clinical Nuclear Medicine

Volumn 39, Issue 5, 2014, Pages

  Chen, Shang Wen ^a,b,c   Hsieh, Te Chun ^d,e   Yen, Kuo Yang ^d,e   Liang, Ji An ^a,b   Kao, Chia Hung ^b,d  

^a China Medical University Hospital   (China)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

FDG PET CT; pharyngeal carcinoma; prognostic factor; radiotherapy; total lesion glycolysis

Indexed keywords

CETUXIMAB; CISPLATIN; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HYPOPHARYNX CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; ONCOLOGICAL PARAMETERS; OROPHARYNX CANCER; OVERALL SURVIVAL; PET-CT SCANNER; PRIMARY TUMOR; RECURRENCE FREE SURVIVAL; TOTAL LESION GLYCOLYSIS; TREATMENT OUTCOME; TUMOR VOLUME; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; GLYCOLYSIS; MULTIMODAL IMAGING; PHARYNGEAL NEOPLASMS; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; SCINTISCANNING; TUMOR RECURRENCE;

ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; GLYCOLYSIS; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM RECURRENCE, LOCAL; PHARYNGEAL NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84898543113     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0000000000000243     Document Type: Article

References (14)

1. Schinagl DA, Span PN, Oyen WJ, et al. Can FDG PET predict radiation treatment outcome in head and neck cancer? Results of a prospective study. Eur J Nucl Med Mol Imaging. 2011;38:1449-1458.
2. La TH, Filion EJ, Turnbull BB, et al. Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2009;74:1335-1341.
3. Kao CH, Lin SC, Hsieh TC, et al. Use of pretreatment metabolic tumor volumes to predict the outcome of pharyngeal cancer treated by definitive radiotherapy. Eur J Nucl Med Mol Imag. 2012;39:1297-1305.
4. Larson SM, Erdi Y, Akhurst T, et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging: the visual response score and the change in total lesion glycolysis. Clin Positron Imaging. 1999;2:159-171.
5. Lim R, Eaton A, Lee NY, et al. 18F-FDG PET/CT metabolic tumor volume and total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma. J Nucl Med. 2012;53:1506-1513.
6. Moon SH, Choi JY, Lee HJ, et al. Prognostic value of 18F-FDG PET/CT in patients with squamous cell carcinoma of the tonsil: comparison of volumebased metabolic parameters. Head Neck. 2013;35:15-22.
7. Chan SC, Chang JT, Lin CY, et al. Clinical utility of 18F-FDG PET parameters in patients with advanced nasopharyngeal carcinoma: predictive role for different survival endpoints and impact on prognostic stratification. Nucl Med Com. 2011;32:989-996.
8. Higgins KA, Hoang JK, Roach MC, et al. Analysis of pretreatment FDG-PET SUV parameters in head and neck cancer: tumor SUVMEAN has superior prognostic value. Int J Radiat Oncol Biol Phys. 2012;82:548-553.
9. Chung MK, Jeong HS, Park SG, et al. Metabolic tumor volume of [18F]- fluorodeoxyglucose positron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer. Clin Cancer Res. 2009;15:5861-5868.
10. Patel DA, Chang ST, Goodman KA, et al. Impact of integrated PET/CT on variability of target volume delineation in rectal cancer. Technol Cancer Res Treat. 2007;6:31-36.
11. Brockstein B, Haraf DJ, Rademaker AW, et al. Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann Oncol. 2004;15:1179-1186.
12. Kahraman D, Holstein A, Scheffler M, et al. Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer treated with erlotinib. Clin Nucl Med. 2012;37:1058-1064.
13. Maffione AM, Ferretti A, Grassetto G, et al. Fifteen different 18F-FDG PET/CT qualitative and quantitative parameters investigated as pathological response predictors of locally advanced rectal cancer treated by neoadjuvant chemoradiation therapy. Eur J Nucl Med Mol Imaging. 2013;40:853-864.
14. Chien CY, Su CY, Fang FM, et al. Lower prevalence but favorable survival for human papillomavirusYrelated squamous cell carcinoma of tonsil in Taiwan. Oral Oncol. 2008;44:174-179.